FDA Approves INTELENCE Tablets for Treatment-Experienced Pediatric Patients with HIV-1

Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S. Food and Drug Administration has approved INTELENCE to be administered in combination with other antiretroviral medications for treatment of human immunodeficiency virus 1 in treatment-experienced pediatric patients (6 years to less than 18 years old) who are experiencing virologic failure with HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor and other ARVs.